Every Form 4 that Boston Scientific Corporation (BSX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BSX filings page.
BOSTON SCIENTIFIC CORP (BSX) reported that EVP, Global Operations Padraig Andrew O'Connor had 1,171 restricted stock units convert into 1,171 shares of common stock on September 2, 2026. Each unit represents a commitment to issue one Boston Scientific share. Of the shares issued, 567 shares were delivered or withheld to pay the exercise price or tax liability, with the remaining shares held directly. Following the transaction, 3,516 restricted stock units remain outstanding and are scheduled to be settled in four equal annual installments beginning on September 2, 2026. No Rule 10b5-1 trading plan is reported.
BOSTON SCIENTIFIC CORP (BSX) director Susan E. Morano reported purchasing 2,040 shares of common stock on 2026-08-25 in an open-market or private transaction at $49.2195 per share. Following this buy, she directly holds 13,784 shares of Boston Scientific common stock. The Rule 10b5-1 trading plan checkbox was not marked for this transaction.
BOSTON SCIENTIFIC CORP executive Emily Woodworth, SVP, Global Controller and CAO, reported a discretionary acquisition of 2,930 shares of common stock on 2026-08-11 at $51.19 per share. The shares were acquired indirectly through a rebalance in the company’s 401(k) Retirement Savings Plan, bringing her indirect 401(k) holdings to 2,930 shares.
A separate holding entry shows 3,123 shares held directly, which includes shares acquired under the Boston Scientific Employee Stock Purchase Plan based on the most current data available.
Boston Scientific EVP and CFO Jonathan Monson reported an indirect acquisition of 9,908 shares of Boston Scientific common stock on 2026-08-10 at $50.46 per share. The footnote states this was a discretionary rebalancing election under the company’s 401(k) Retirement Savings Plan, treated as a discretionary transaction under Rule 16b-3(f). After this transaction, he indirectly holds 9,908 shares through the 401(k) and separately reports 39,063 shares held directly.
Boston Scientific director David C. Habiger purchased 2,100 shares of common stock on August 5, 2026 in an open-market transaction at a weighted average price of $47.589 per share, with individual trade prices between $47.21 and $47.98. Following this purchase, he directly owns 17,160 shares.
Boston Scientific Corp director David C. Habiger reported open-market purchases of Common Stock on two days in August 2026. He bought 1,042 shares on August 3 at a weighted average price of $48.0655 per share and 140 shares on August 4 at a weighted average price of $48.5879 per share. Each trade was executed through multiple transactions within stated price ranges, with detailed per-trade pricing available on request.
Boston Scientific CEO Michael F. Mahoney purchased 186,240 shares of common stock on August 3, 2026 at a weighted average price of $48.3323 per share, with individual trades between $47.87 and $48.47. After this open-market buy, he directly owns 1,590,024 shares and indirectly holds 22,119 shares via a 401(k) Retirement Savings Plan following a discretionary rebalancing transaction at $48.4300 per share.
Boston Scientific Corp director Edward J. Ludwig purchased 5,000 shares of common stock on July 31, 2026 at an average price of $45.4799 per share. After this open-market or private transaction, he directly owns 30,359 shares. The trade was not reported under a Rule 10b5-1 plan.
Boston Scientific Corp executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported a discretionary acquisition of 64,198 shares of common stock on 2026-07-31 through a rebalance of his holdings under the company’s 401(k) Retirement Savings Plan at $46.73 per share. These shares are held indirectly via the 401(k), which now reflects that balance. Separate entries show 213,907 shares held directly and 5,234 shares held by his child, with a footnote stating he disclaims beneficial ownership of the child’s shares.
Boston Scientific EVP and CFO Jonathan Monson reported routine equity compensation activity involving restricted stock units. He exercised 2,087 restricted stock units into 2,087 shares of common stock and, in a related tax-withholding disposition, 1,010 shares were withheld at a price of $43.06 per share to cover tax obligations. After these transactions, he directly holds 39,063 shares of common stock and 6,263 restricted stock units, which each represent a commitment by the company to issue one share of common stock in the future, with shares to be issued in four equal annual installments beginning on July 1, 2026.
Boston Scientific Chairman, President & CEO Michael F. Mahoney reported a large charitable-style transfer of stock. He made a bona fide gift of 386,755 shares of Boston Scientific common stock on May 28, 2026 to The Michael F. Mahoney Term Irrevocable Trust - 2026, which is administered by an independent trustee.
After this transaction, Mahoney continues to hold 1,403,784 shares of Boston Scientific common stock directly. The gift is a non-market disposition with no sale proceeds reported, meaning it does not reflect open-market buying or selling activity in the stock.
Boston Scientific director Cheryl Pegus bought 1,770 shares of common stock in an open-market transaction. The purchase occurred at a weighted average price of about $56.49 per share, across multiple trades priced between $56.49 and $56.5009. After this transaction, she directly owns 1,770 shares.
BOSTON SCIENTIFIC CORP director Edward J. Ludwig made an open-market purchase of 3,580 shares of Common Stock at $56.68 per share. The transaction occurred on May 20, 2026 and increased his direct ownership to 25,359 shares following the trade.
Boston Scientific Corp director David C. Habiger reported buying additional company stock in two recent open-market transactions. He purchased 2,200 shares of Common Stock on May 19, 2026 at a weighted average price of $56.9451 per share, and 2,250 shares on May 20, 2026 at a weighted average price of $55.9195 per share. According to the filing, individual trades on each day occurred within narrow price ranges around these averages. Following these purchases, Habiger directly owns 13,878 Boston Scientific common shares.
Zane Ellen M reported acquisition or exercise transactions in this Form 4 filing.
BOSTON SCIENTIFIC CORP director Ellen M. Zane received an annual equity award of common stock. She was granted 3,800 shares of restricted stock on May 7, 2026 at no cash cost per share. The award reflects a value of $215,000 divided by the closing price of the common stock on the grant date and will vest in full at the next annual meeting of stockholders. After this grant, she directly holds 27,934 common shares.
WICHMANN DAVID S reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director David S. Wichmann received an annual equity award of 3,800 shares of Common Stock on May 7, 2026. The grant was made at no cash cost to him and is structured as restricted stock that vests in full at the next annual stockholders’ meeting.
After this award, he directly owns 45,382 shares. The filing notes the grant reflects a value of $215,000, calculated by dividing that amount by the closing price of Boston Scientific’s common stock on the grant date.
Boston Scientific director Christophe Pierre Weber reported equity-based compensation grants. On May 7, 2026, he received 1,140 shares of restricted stock in lieu of 80% of his yearly cash retainer, reflecting a value of approximately $100,000 based on the grant-date closing price.
He also received an annual equity award of 1,767 restricted shares, tied to a program value of $215,000, with $64,500 representing 30% of that award. In addition, he was granted 2,660 Deferred Stock Units, tied to $150,500 (70% of the annual equity award), which convert into common shares after his service on the board ends. All equity awards vest in full at the next annual meeting of stockholders.
Smith Cathy R reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Cathy R. Smith received equity compensation in the form of deferred stock units. On 2026-05-07, she was granted 2,209 deferred stock units tied to common stock as an annual equity award valued at $215,000, plus 3,800 additional deferred stock units granted in lieu of $125,000 of yearly cash compensation.
Each deferred stock unit represents a commitment to issue one share of Boston Scientific common stock. Both awards vest in full at the next annual meeting of stockholders, with shares delivered only after she leaves the Board under the Non-Employee Director Deferred Compensation Plan. Following these grants, reported deferred stock unit balances in the respective plans were 6,888 and 4,679 units.
Pegus Cheryl reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Cheryl Pegus received two compensation grants of deferred stock units, not open-market purchases or sales. On May 7, 2026, she was awarded 3,800 deferred stock units representing an annual equity award valued at $215,000, based on the closing share price that day. She also received 1,281 deferred stock units granted in lieu of 50% of her yearly cash and committee chair retainers, reflecting a value of $72,500 divided by the same closing price. Each deferred stock unit represents a commitment to issue one share of Boston Scientific common stock, vesting in full at the next annual stockholders’ meeting, with shares delivered after she leaves Board service under the Non-Employee Director Deferred Compensation Plan. Following these awards, she directly holds 10,998 deferred stock units.
Morano Susan E reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Susan E. Morano reported two equity compensation grants of common stock. She received 1,281 shares as an annual equity award of restricted stock and 3,800 shares of restricted stock granted in lieu of 50% of her yearly cash compensation. Both grants vest in full at the next annual meeting of stockholders.
The annual equity award reflects a value of $215,000 based on the closing share price on the grant date. The stock granted in place of cash has an approximate value of $72,500, tied to the non-employee director cash retainer and committee chair retainer. These are compensation-related awards, not open‑market share purchases or sales.
Mega Jessica L reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Jessica L. Mega received an annual equity award of 3,800 shares of Common Stock. The award is in the form of restricted stock that will vest in full at the next annual meeting of stockholders. The footnote explains the grant reflects a value of $215,000 divided by the closing price of the common stock on the grant date. Following this compensation-related award, she directly holds 12,035 shares of Boston Scientific common stock.
Habiger David C reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director David C. Habiger received an annual equity award of 3,800 shares of common stock. The award is in the form of restricted stock that will vest in full at the next annual meeting of stockholders. According to the filing, the grant reflects a value of $215,000, based on the closing price of the common stock on the grant date. After this grant, Habiger directly holds 9,428 shares of Boston Scientific common stock.
Boston Scientific director Edward J. Ludwig received an annual equity award in the form of restricted stock. On the grant date, he acquired 3,800 shares of common stock at no cash cost as a grant or award. The award reflects a value of $215,000 divided by the closing price of the common stock on the grant date. These restricted shares vest in full at the next annual meeting of stockholders. Following this grant, Ludwig directly holds 21,779 shares of Boston Scientific common stock.
Boston Scientific EVP Padraig Andrew O'Connor reported routine equity compensation activity involving restricted stock units. On May 2, 2026, he exercised awards covering 1,802 restricted stock units, receiving the same number of shares of Boston Scientific common stock.
To satisfy tax obligations related to this vesting, 872 common shares were disposed of at $56.50 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, O'Connor directly holds 7,024 shares of common stock.
BOSTON SCIENTIFIC CORP executive Arthur C. Butcher reported routine equity compensation activity. On May 2, 2026, he exercised 2,102 Restricted Stock Units, receiving the same number of common shares. These RSUs each represent a commitment to issue one share of Boston Scientific common stock.
To cover tax obligations, 1,007 common shares were disposed of through a tax-withholding transaction at $56.50 per share, which is not an open-market sale. After these transactions, he holds 56,887 common shares directly and 20,228 shares indirectly through the company’s 401(k) Retirement Savings Plan.
Boston Scientific director Cheryl Pegus reported an equity award in the form of deferred stock units. On March 2, 2026, she acquired 24 deferred stock units at a stated price of $0.00 per unit, reflecting $1,845.25 of compensation based on the common stock’s closing price that day.
Each deferred stock unit represents a commitment by Boston Scientific to issue one share of common stock in the future. These units were granted in lieu of 50% of her yearly cash compensation, vest in full at the next annual stockholder meeting, and the underlying shares will be delivered after she leaves the Board under the company’s non-employee director deferred compensation plan. Following this grant, her reported direct holdings total 5,917 deferred stock units.
Morano Susan E reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Susan E. Morano received an equity grant of 24 shares of common stock on March 2, 2026, at no cash cost to her. The award is restricted stock granted in lieu of 50% of her cash compensation, valued at $1,845.25 based on the closing share price on the grant date, and will vest in full at the next annual meeting of stockholders. Following this grant, she directly holds 6,663 Boston Scientific shares.
Boston Scientific director Christophe Pierre Weber reported receiving two restricted stock grants as a non-employee director. He acquired 556 shares of common stock as an initial equity award with an approximate value of $42,419.50, prorated under the company’s non-employee director compensation program.
Weber also received 323 restricted shares in lieu of 100% of his prorated yearly cash retainer, with an approximate value of $24,662.50. Both grants were based on the closing stock price on the grant date and are scheduled to vest in full at the company’s 2026 annual meeting of stockholders.
Boston Scientific director Cathy R. Smith received two grants of deferred stock units as part of her non-employee director compensation. She acquired 556 deferred stock units valued at approximately $42,419.50 as an equity award and 323 deferred stock units valued at approximately $24,662.50 in lieu of yearly cash compensation. Each deferred stock unit represents a commitment to issue one share of common stock. Both grants are prorated from her appointment date to the 2026 annual meeting and vest in full at the next annual meeting, with shares delivered after she leaves Board service under the company’s deferred compensation plan.
Boston Scientific (BSX) senior vice president Emily Woodworth reported equity compensation activity involving restricted stock units and common stock. On March 1, 2026, she exercised or converted 838 restricted stock units, which represent a commitment to issue one share of common stock for each unit.
The same day, she acquired 838 shares of Boston Scientific common stock through this derivative exercise. Also on March 1, 372 shares of common stock were disposed of at $76.85 per share in a transaction classified as payment of tax liability by delivering securities. After these transactions, she directly owned 1,676 restricted stock units and 2,859 common shares.
Boston Scientific executive Arthur C. Butcher reported a discretionary rebalancing transaction in the company’s 401(k) plan involving 6,851 shares of common stock at $75.76 per share. This was an indirect transaction under the company’s 401(k) Retirement Savings Plan, treated as a discretionary transaction under Rule 16b-3(f).
Following this plan-related activity, his indirect 401(k) holdings were 20,205 shares of Boston Scientific common stock, and his directly held position was 55,792 shares. The filing reflects a retirement-plan allocation decision rather than a traditional open-market purchase or sale.
Boston Scientific EVP Padraig Andrew O'Connor reported multiple equity award transactions. On February 13, 14, and 16, 2026, restricted stock units covering 500, 1,190, and 905 units were exercised or converted into an equal number of Boston Scientific common shares at a stated price of $0.00 per share.
Related Form 4 entries show dispositions of 199, 449, and 339 common shares at $74.73 per share, characterized as payments of tax liability by delivering shares rather than open-market sales. Footnotes explain that each restricted stock unit represents a commitment to issue one share, generally in four equal annual installments beginning on specified February anniversaries of the grant dates.
Boston Scientific SVP Emily Woodworth reported several equity transactions involving restricted stock units and common stock. On February 13–16, 2026, she exercised restricted stock units that convert into an equal number of Boston Scientific common shares, with individual transactions including 1,413, 661, and 637 units. Corresponding common stock entries show the same share amounts acquired at a stated price of $0.0000 per share, reflecting non-cash derivative exercises. Additional common stock entries coded “F” cover 690, 296, and 283 shares delivered at $74.73 per share to satisfy tax liabilities rather than open-market sales. Footnotes state that each restricted stock unit represents a commitment to issue one share of common stock, generally in four equal annual installments beginning on specific grant anniversaries.
Boston Scientific EVP and CFO Jonathan Monson reported a series of equity award transactions. On February 13, 14 and 16, 2026, restricted stock units were converted into common stock in blocks of 1,766, 1,058 and 990 shares at $0.0000 per share, reflecting vesting of prior grants. On each date, portions of the resulting common shares (788, 470 and 440 shares) were disposed of at $74.73 per share to satisfy tax obligations through share withholding. Following these transactions, Monson directly owned 37,986 shares of Boston Scientific common stock.
Boston Scientific senior vice president and chief HR officer Miriam O'Sullivan reported multiple equity award transactions in mid‑February. She exercised restricted stock units into 588, 1,124, and 990 shares of common stock on February 13, 14, and 16, 2026 at a price of $0.00 per share.
To cover tax obligations, she disposed of 200, 329, and 291 common shares on the same dates through tax‑withholding transactions at $74.73 per share. After these moves, she directly held 17,302 Boston Scientific shares and indirectly held 1,731 shares through her spouse.
Boston Scientific Corp Chairman, President & CEO Michael F. Mahoney reported multiple equity award and vesting transactions. On February 13, 2026, he acquired 132,190 shares of common stock as a grant and another 8,832 shares through the conversion of restricted stock units, while 132,099 shares of common stock were withheld at $74.73 per share to cover tax obligations.
On February 14, 2026, 16,524 restricted stock units converted into 16,524 common shares, with 7,990 shares withheld for taxes at $74.73 per share. On February 16, 2026, 16,265 restricted stock units converted into common stock and 7,865 shares were similarly withheld for taxes at $74.73 per share.
The filing notes performance share units granted in February 2023 under organic net sales and total shareholder return programs, for which performance and service conditions were satisfied as of February 13, 2026. An additional 213,679 common shares are reported as held indirectly by trust.
Boston Scientific executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported multiple stock-based compensation transactions. He acquired Boston Scientific common stock through exercises of restricted stock units and performance share units, as well as grants totaling 34,898 shares of common stock on February 13, 2026.
On February 13, 14, and 16, 2026, he also had shares of common stock withheld to satisfy tax liabilities, disposing of 33,104, 1,990, and 1,806 shares at $74.73 per share, respectively, as tax-withholding dispositions rather than open-market sales. After these transactions, he directly held 213,907 shares of common stock, and 5,234 additional shares were reported as held indirectly by his child, for which he disclaims beneficial ownership.
Boston Scientific EVP Arthur C. Butcher reported multiple equity transactions in company stock and units. On February 13, 2026, he acquired 25,380 shares of common stock in two grant or award acquisitions, and also acquired shares through exercises of restricted stock units tied to long‑term incentive programs. He disposed of 25,150 shares of common stock on February 13, 2026 and smaller amounts on later dates to cover tax liabilities at $74.73 per share. Following these moves, he directly held 55,792 shares of common stock and indirectly held 13,354 shares through the company 401(k) plan.
Boston Scientific EVP, GC and Corporate Secretary Vance R. Brown reported multiple equity compensation transactions. On February 13–16, 2026, he acquired Boston Scientific common stock through the exercise and conversion of restricted stock units and performance share units, and through grants and awards, all at a stated price of $0.00 per share.
On these dates, shares of common stock were also disposed of at $74.73 per share to satisfy tax liabilities by delivering securities. Footnotes explain that performance share units granted on February 14, 2023 vested based on three-year total shareholder return and organic net sales performance through December 31, 2025, subject to a three-year service period satisfied on February 13, 2026. Each restricted stock unit represents a commitment to issue one share in four equal annual installments beginning on specified anniversaries of the grant dates.
Boston Scientific SVP and Chief HR Officer Miriam O'Sullivan reported several equity compensation transactions dated February 12, 2026. She acquired 961 shares of Boston Scientific common stock at $0.0000 through the exercise of restricted stock units, then had 338 shares withheld at $74.12 per share to cover tax obligations, leaving 15,420 directly held shares plus 1,731 held indirectly by her spouse.
On the derivative side, she exercised 961 restricted stock units, ending with 1,924 restricted stock units directly owned. She also received a new grant of 4,722 restricted stock units and a stock option award for 11,143 shares. The restricted stock units and options vest in four equal annual installments beginning on February 12, 2027, with the earlier RSU grant delivering shares in four equal installments starting February 12, 2025.
Boston Scientific SVP Emily Woodworth reported multiple equity awards and an RSU exercise. On February 12, 2026, she exercised 481 restricted stock units into 481 common shares at an exercise price of $0.0000 and had 242 shares withheld at $74.12 per share to cover tax obligations, leaving 951 common shares directly owned. She also received 6,071 new restricted stock units and a grant of 5,584 stock options with a $74.12 exercise price, each vesting in four equal annual installments starting February 12, 2027.
Boston Scientific executive Padraig Andrew O'Connor, EVP Global Operations, reported several equity compensation transactions dated February 12, 2026. He exercised 1,058 restricted stock units into common shares and had 457 shares withheld at $74.12 per share to cover tax obligations, leaving 4,486 common shares directly owned.
He now directly holds 2,116 restricted stock units from earlier awards. On the same date, he received a new grant of 5,059 restricted stock units and 11,939 stock options. The RSUs and options vest in four equal annual installments beginning on February 12, 2027, with each unit or option tied to one share of common stock.
Boston Scientific EVP and CFO Jonathan Monson reported several equity transactions on February 12, 2026. He exercised 1,154 restricted stock units into common shares at a conversion price of $0.0000, then had 573 common shares withheld at $74.12 per share to cover tax obligations, leaving 35,870 common shares held directly.
Monson also acquired new equity awards. He received 11,805 restricted stock units, each representing one future share of Boston Scientific common stock, and was granted stock options for 27,857 shares. Both the new RSUs and options vest in four equal annual installments beginning February 12, 2027.
Boston Scientific Chairman, President & CEO Michael F. Mahoney reported several equity compensation transactions dated February 12, 2026. He acquired 13,704 shares of common stock through the exercise of restricted stock units at $0.0000 per share, then disposed of 6,626 shares at $74.12 per share to cover tax obligations, leaving 1,418,813 common shares held directly.
Mahoney also received a new grant of 55,652 restricted stock units and a stock option for 131,329 shares with an exercise price of $74.12 per share, both vesting in four equal annual installments beginning February 12, 2027. In addition, 213,679 common shares are held indirectly in a trust.
Boston Scientific EVP & Group President, Cardiology Joseph Michael Fitzgerald reported equity compensation and related share movements. On February 12, 2026, he exercised 3,462 restricted stock units, receiving the same number of Boston Scientific common shares. To cover tax obligations, 1,612 common shares were disposed of at $74.12 per share through share withholding, leaving him with 169,892 common shares held directly. He also received new awards of 18,550 restricted stock units and a stock option for 43,776 shares, each vesting in four equal annual installments beginning on February 12, 2027. Following these transactions, he directly holds 6,924 restricted stock units and 18,550 restricted stock units from the new grant, plus the 43,776-share stock option. An additional 5,234 common shares are reported as held indirectly by his child, and he disclaims beneficial ownership of those shares.
Butcher Arthur C reported multiple insider transaction types in a Form 4 filing for BSX. The filing lists transactions totaling 57,681 shares at a weighted average price of $74.12 per share. Following the reported transactions, holdings were 5,386 shares.
Boston Scientific executive Vance R. Brown, EVP, GC and Corporate Secretary, reported equity compensation changes tied to restricted stock units and options. On February 12, 2026, 1,442 restricted stock units were exercised into 1,442 shares of common stock, and 488 shares were disposed of to cover tax withholding at $74.12 per share.
Following these transactions, Brown directly held 34,405 shares of common stock. He also received new grants of 7,420 restricted stock units and 17,510 stock options with a $74.12 exercise price, each vesting in four equal annual installments beginning February 12, 2027.
Boston Scientific’s Chairman, President & CEO Michael F. Mahoney reported routine equity transactions in company stock. On February 2, 2026, he exercised stock options for 49,407 shares at $24.55 and 46,347 shares at $27.09, converting them into common stock.
That same day, he sold 1,200 shares at a weighted average price of $94.0567 and 159,701 shares at a weighted average price of $93.4905. The filing states these trades were made under a pre-established Rule 10b5‑1 trading plan adopted on August 29, 2025.
After these transactions, Mahoney directly owned 1,411,735 Boston Scientific common shares and had stock options for 231,739 and 98,814 shares from prior grants. He also indirectly held 213,679 shares through a trust.
Boston Scientific executive reports option exercises and share sale. An officer of Boston Scientific Corp. exercised multiple stock options on 12/01/2025, acquiring 17,313 shares of common stock at exercise prices ranging from $17.26 to $27.09 per share. On the same date, the executive sold 17,313 shares of common stock in an open-market transaction at a weighted average price of $101.5531 per share under a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024. After these transactions, the executive directly held 23,600 shares of Boston Scientific common stock and indirectly held 13,354 shares through the company’s 401(k) Retirement Savings Plan.
Boston Scientific Corp. insider activity shows the SVP and Chief HR Officer reporting a stock transfer. On 11/28/2025, the officer disposed of 260 shares of common stock in a transaction coded "G," which typically indicates a gift, at a reported price of $0.0000 per share. After this transaction, the officer directly owned 14,797 shares and indirectly owned 1,731 shares through a spouse. A footnote explains that the direct holdings include shares acquired on June 30, 2025 under the company’s Employee Stock Purchase Plan.